New diabetes clinical trial: SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Published on: September 29, 2025 at 11:00PM
Conditions: Acute Myocardial Infarction (AMI); Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin); Drug: DPP4 inhibitors
Sponsors: Yonsei University; Chong Kun Dang Pharmaceutical Corp.; Health Insurance Review & Assessment Service
Active, not recruiting
https://ift.tt/OqHYfdy
Conditions: Acute Myocardial Infarction (AMI); Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin); Drug: DPP4 inhibitors
Sponsors: Yonsei University; Chong Kun Dang Pharmaceutical Corp.; Health Insurance Review & Assessment Service
Active, not recruiting
https://ift.tt/OqHYfdy
Comments
Post a Comment